Testosterone and erectile physiology

References

• Morales A, Lunenfeld B. Androgen replacement therapy in aging men with secondary hypogonadism. Aging Male 2001; 4: 151–162
   Google Scholar
• Matsumoto A M. Andropause: Clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci 2002; 57: M76–M99
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients – 2002 update. Endocr Pract 2002; 8: 440–456
   PubMedGoogle Scholar
• Haji M, Tanaka S, Nishi Y, Yanase T, Takayanagi R, Hasegawa Y, Sasamoto S, Nawata H. Sertoli cell function declines earlier than Leydig cell function in aging Japanese men. Maturitas 1994; 18: 143–153
   PubMedGoogle Scholar
• Kaufman J M, Vermeulen A. Declining gonadal function in elderly men. Baillieres Clin Endocrinol Metab 1997; 11: 289–309
   PubMed Web of Science ®Google Scholar
• Wishart J M, Need A G, Horowitz M, Morris H A, Nordin B E. Effect of age on bone density and bone turnover in men. Clin Endocrinol (Oxf) 1995; 42: 141–146
   PubMed Web of Science ®Google Scholar
• Tibblin G, Adlerberth A, Lindstedt G, Bjorntorp P. The pituitary-gonadal axis and health in elderly men: A study of men born in 1913. Diabetes 1996; 45: 1605–1609
   PubMed Web of Science ®Google Scholar
• Ferrini R L, Barrett-Connor E. Sex hormones and age: A cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol 1998; 147: 750–754
   PubMed Web of Science ®Google Scholar
• Gray A, Berlin J A, McKinlay J B, Longcope C. An examination of research design effects on the association of testosterone and male aging: Results of a meta-analysis. J Clin Epidemiol 1991; 44: 671–684
   PubMed Web of Science ®Google Scholar
• Morley J E, Kaiser F E, Perry H M, 3rd, Patrick P, Morley P M, Stauber P M, Vellas B, Baumgartner R N, Garry P J. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997; 46: 410–413
   PubMed Web of Science ®Google Scholar
• Zmuda J M, Cauley J A, Kriska A, Glynn N W, Gutai J P, Kuller L H. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol 1997; 146: 609–617
   PubMed Web of Science ®Google Scholar
• Gray A, Feldman H A, McKinlay J B, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991; 73: 1016–1025
   PubMed Web of Science ®Google Scholar
• Wu A H, Whittemore A S, Kolonel L N, John E M, Gallagher R P, West D W, Hankin J, Teh C Z, Dreon D M, Paffenbarger R S, Jr. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev 1995; 4: 735–741
   PubMed Web of Science ®Google Scholar
• Harman S M, Metter E J, Tobin J D, Pearson J, Blackman M R. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724–731
   PubMed Web of Science ®Google Scholar
• Morley J E, Charlton E, Patrick P, Kaiser F E, Cadeau P, McCready D, Perry H M, III. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239–1242
   PubMed Web of Science ®Google Scholar
• Korenman S G, Morley J E, Mooradian A D, Davis S S, Kaiser F E, Silver A J, Viosca S P, Garza D. Secondary hypogonadism in older men: Its relation to impotence. J Clin Endocrinol Metab 1990; 71: 963–969
   PubMed Web of Science ®Google Scholar
• Bodie J, Lewis J, Schow D, Monga M. Laboratory evaluations of erectile dysfunction: An evidence based approach. J Urol 2003; 169: 2262–2264
   PubMed Web of Science ®Google Scholar
• Dobs A S, Dempsey M A, Ladenson P W, Polk B F. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988; 84: 611–616
   PubMed Web of Science ®Google Scholar
• Martin M E, Benassayag C, Amiel C, Canton P, Nunez E A. Alterations in the concentrations and binding properties of sex steroid binding protein and corticosteroid-binding globulin in HIV+ patients. J Endocrinol Invest 1992; 15: 597–603
   PubMed Web of Science ®Google Scholar
• Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 5462–5468
   PubMed Web of Science ®Google Scholar
• Feldman H A, Goldstein I, Hatzichristou D G, Krane R J, McKinlay J B. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61
   PubMed Web of Science ®Google Scholar
• Guay A T, Velasquez E, Perez J B. Characterization of patients in a medical endocrine-based center for male sexual dysfunction. Endocr Pract 1999; 5: 314–321
   PubMedGoogle Scholar
• Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158: 1764–1767
   PubMed Web of Science ®Google Scholar
• Nehra A. Treatment of endocrinologic male sexual dysfunction. Mayo Clin Proc 2000; 75(Suppl.): S40–S45
   Google Scholar
• Shabsigh R. Hypogonadism and erectile dysfunction: The role for testosterone therapy. Int J Impot Res 2003; 15(Suppl. 4)S9–S13
   Google Scholar
• Traish A M, Park K, Dhir V, Kim N N, Moreland R B, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999; 140: 1861–1868
   PubMed Web of Science ®Google Scholar
• Traish A M, Munarriz R, O'Connell L, Choi S, Kim S W, Kim N N, Huang Y H, Goldstein I. Effects of medical or surgical castration on erectile function in an animal model. J Androl 2003; 24: 381–387
   PubMed Web of Science ®Google Scholar
• Lugg J A, Rajfer J, Gonzalez-Cadavid N F. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology 1995; 136: 1495–1501
   PubMed Web of Science ®Google Scholar
• Park K H, Kim S W, Kim K D, Paick J S. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int 1999; 83: 327–333
   PubMed Web of Science ®Google Scholar
• Reilly C M, Lewis R W, Stopper V S, Mills T M. Androgenic maintenance of the rat erectile response via a non-nitric-oxide-dependent pathway. J Androl 1997; 18: 588–594
   PubMedGoogle Scholar
• Aversa A, Isidori A M, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003; 58: 632–638
   PubMed Web of Science ®Google Scholar
• Foresta C, Caretta N, Rossato M, Garolla A, Ferlin A. Role of androgens in erectile function. J Urol 2004; 171: 2358–2362, quiz 2435
   PubMed Web of Science ®Google Scholar
• Guay A T, Perez J B, Jacobson J, Newton R A. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 2001; 22: 793–797
   PubMed Web of Science ®Google Scholar
• Marbury T, Hamill E, Bachand R, Sebree T, Smith T. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel. Biopharm Drug Dispos 2003; 24: 115–120
   PubMed Web of Science ®Google Scholar